FDA to review application for allergic conjunctivitis medication

IRVINE, Calif. A committee of the Food and Drug Administration will review the application for a new drug to treat itching of the eyes in patients with allergic conjunctivitis.

ISTA Pharmaceuticals announced Monday that it had received notification from the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee that it would review the application for Bepreve (bepotastine ophthalmic solution) on June 26. The company filed the application in November.

The company said the application includes data from a phase 3 study showing the drug was effective in controlling itching of the eyes.